参考文献:[1]Djanani A,Eller S,Öfner D,et al.The role of braf in metastatic colorectal carcinoma–past,present,and future[J].International Journal of Molecular Sciences,2020,21(23):9001.[2]Luu L J,Price T J.BRAF Mutation and Its Importance in Colorectal Cancer[M]//Advances in the Molecular Understanding of Colorectal Cancer.IntechOpen,2019.[3]Jones J C,Renfro L A,Al-Shamsi H O,et al.Non-V600BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer[J].Journal of Clinical Oncology,2017,35(23):2624-2630.[4]Mauri G,Bonazzina E,Amatu A,et al.The evolutionary landscape of treatment for BRAFV600E mutant metastatic colorectal cancer[J].Cancers,2021,13:137.[5]Corcoran RB,Atreya CE,Falchook GS,et al.Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer[J].J Clin Oncol.2015 Dec 1;33(34):4023-31.[6]Corcoran RB,AndréT,Atreya CE,et al.Combined BRAF,EGFR,and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer[J].Cancer Discov.2018 Apr;8(4):428-443.[7]Van Cutsem,Tabernero J,Taieb J,et al.ANCHOR CRC:a single-arm,phase 2 study of encorafenib,binimetinib plus cetuximab in previously untreated BRAFV600E–mutant metastatic colorectal cancer.2021 WCGIC,O-10.[8]Tabernero J,Grothey A,Van Cutsem E.Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer:Updated Survival Results and Subgroup Analyses from the BEACON Study.J Clin Oncol,2021,39:273-284.*此文仅用于向医学人士提供科学信息,不代表本平台观点